1 results match your criteria: "P.B.G.) and University of Washington[Affiliation]"
Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.
N Engl J Med
July 2018
From Sanofi Pasteur, Marcy l'Etoile (S. Sridhar, E.L., A.M.), and Soladis, Lyon (T.M.) - both in France; Fred Hutchinson Cancer Research Center (A.L., Z.M., T.W., P.B.G.) and University of Washington, Seattle (T.W., P.B.G.) - both in Seattle; Sanofi Pasteur, Swiftwater, PA (M.Z., M.B., S. Savarino, F.N., J.C., S.G., C.A.D.); Sanofi Pasteur, Montevideo, Uruguay (B.Z.); Sanofi Pasteur, Toronto (A.K.); Sanofi Pasteur, Mexico City (C.M.); Sanofi Pasteur, Singapore, Singapore (C.F., A.B., S.-P.N.); Sanofi Pasteur, Bogota, Colombia (M.C.); and Sanofi Pasteur, Bangkok, Thailand (D.C.).
Background: In efficacy trials of a tetravalent dengue vaccine (CYD-TDV), excess hospitalizations for dengue were observed among vaccine recipients 2 to 5 years of age. Precise risk estimates according to observed dengue serostatus could not be ascertained because of the limited numbers of samples collected at baseline. We developed a dengue anti-nonstructural protein 1 (NS1) IgG enzyme-linked immunosorbent assay and used samples from month 13 to infer serostatus for a post hoc analysis of safety and efficacy.
View Article and Find Full Text PDF